Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

MGC Pharmaceuticals "totally understands" CimetrA after MoA study

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA platform.

Lisovoder says that the fact MGC "totally understands" CimetrA represents a "very important step" in the development process.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.